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ABSTRACT  
Objectives: The aim of this study was to compare a combination  treatment with CC plus letrozole versus gonadotropins 
in CC-resistant polycystic ovary syndrome (PCOS) patients with regard  to ovulation and clinical pregnancy rate.
Material and methods: One hundred sixteen CC-resistant infertile PCOS patients were evaluated retrospectively. The patients 
were divided into two groups. Group 1 (n = 73) received CC plus letrozole, and Group 2 (n = 43) received gonadotropins.
Results: The ovulation rate in Group 1 was 65/73 (89%), the pregnancy rate was 13/73 (18%), the twin foetuses rate was 
1/73 (1.3%) and the miscarriage rate was 2/73 (2.7%). In Group 2, the ovulation rate was 41/43 (95%), and the pregnancy 
rate was 8/43 (19%) the rate of the twin foetuses was 1/43 (2.3%) and the miscarriage rate was 1/43 (2.3%). There was no 
statistically significant difference in the ovulation (p = 0.25), pregnancy (p = 0.91), twin foetuses (p = 0.89) and miscarriage 
p = 0.89) rates between two groups.
Conclusions: This new drug combination suggests that it may be a lower cost, lower risk alternative treatment that in-
creases the rate of ovulation. Larger randomized clinical trials are needed to provide information on live birth rates of this 
combination.
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common cause 
of infertility and is associated with chronic anovulation and 
hyperandrogenaemia. PCOS affects 6% of women of repro-
ductive age. Clomiphene citrate (CC) is considered the primary 
treatment for inducing ovulation in PCOS patients. CC binds to 
oestrogen receptors and acts as a selective oestrogen receptor 
modulator. As negative feedback from oestrogen decreases, 
gonadotropic hormones are secreted, which induces follicular 
growth. CC has an antiestrogenic effect and has a negative 
effect on endometrial thickness, which is believed to have 
a negative effect on pregnancy despite high ovulation [1–3]. 
Letrozole is another widely used oral drug for ovulation 
induction, with a different mechanism of action to that of CC. 
Letrozole inhibits androgen-oestrogen conversion, which 
leads to the secretion of follicle-stimulating hormone (FSH) 
by suppression of oestrogen production. When adminis-
tered to patients with CC-resistant PCOS, letrozole induces 
ovulation in 54.6–84.4% of patients [4–7].
Gonadotropins can be used in case of resistance to CC 
and letrozole. Luteinized hormone levels may be high in 
CC resistant PCOS patients. Therefore, administration of 
exogenous gonadotropins can further increase FSH and 
luteinizing hormone levels [8]. 
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The aim of this study was to compare a combination 
therapy with CC plus letrozole versus gonadotropins in 
CC-resistant PCOS patients with regard to ovulation and 
clinical pregnancy rate.
MATERIAL AND METHODS
The records of infertile patients who presented to the in-
fertility polyclinic of Gazi Yaşargil Training and Research Hos-
pital in South-Eastern Turkey between February 2017 and 
November 2019 were retrospectively analysed. One hundred 
sixteen CC-resistant infertile PCOS patients were evaluated 
in two groups. In Group 1 there were 73 patients who re-
ceived CC + letrozole treatment, whereas Group 2 consisted 
of the remaining 43 patients who received gonadotropin 
treatment. All patients underwent ovulation induction fol-
lowed by intrauterine insemination.
PCOS was diagnosed according to the Rotterdam crite-
ria: 1) oligomenorrhoea or chronic anovulation, 2) hyperan-
drogenism (clinical or laboratory) and 3) polycystic ovary 
appearance on ultrasound [9]. CC resistance is mentioned 
in the absence of ovulation although 150 mg of CC is taken 
for 5 days in a three-month menstrual cycle period [10]. 
Infertile women with PCOS diagnosed according to Rot-
terdam criteria (2 out of 3) Patients (infertile women) with PCOS 
were diagnosed according to Rotterdam criteria (2 out of 3) 
aged between of 18 and 39 years with no pathological find-
ings (e.g. sub-mucous myomas, endometrial polyps, uterine 
septum, Asherman syndrome, endometriosis or hydrosalpinx) 
detected by ultrasonography or hysterosalpingography and 
normal tubal transition were included in the study. Exclusion 
criteria: with a body mass index (BMI) of > 30 (we directed them 
to the obesity center for their weakening, due to strong insulin 
resistance) pregnancy; current hormonal contraceptionuse; 
other  known  cause of infertility; uncorrected thyroid disease; 
untreated hyperprolactinemia; medical conditions not well 
controlled or not recommended during pregnancy (diabetes 
mellitus, hypertension, endometrial hyperplasia/cancer); al-
lergy or contraindications to letrozole, CC and gonadotropins; 
and male factor in fertility. Male factor infertility was defined 
as a sperm count of less than 15 × 106/mL, total motility less 
than 40% or fewer than 4% normal forms, in accordance with 
the criteria of the World Health Organization [11]. 
The patients were divided into two groups: a CC plus 
letrozole group (Group 1, n = 73) and a gonadotropin treat-
ment group (Group 2, n = 43). In Group 1, the patients re-
ceived a combination of 2.5 mg of letrozole (Femara; Novar-
tis, Basel, Switzerland) for 3 days (days of  menstruation 5–7) 
and 100 mg of CC (Serophene; Serono, Geneva, Switzerland) 
for 5 days (days of  menstruation 3–7 mg) for one treatment 
cycle. Group 2 received recombinant follicle-stimulating 
hormone (rFSH) (Gonal-F 900 pen; Serono, Geneva, Swit-
zerland) from the third day of menstruation.
Farhi et al. [12]. showed that the ideal hCG administration 
time in CC cycles for women with PCOS was in the 18–22 mm 
range. All the patients were evaluated using transvaginal 
ultrasonography on day 7 (the last day of CC plus letrozole 
administration) of menstruation or after the diameter of the 
largest follicle had reached 14 mm. If a dominant follicle was 
present, the patients received a human chorionic gonado-
tropin (HCG) trigger (Ovitrelle; Serono, Geneva, Switzerland) 
in a single dose via subcutaneous route when the follicle size 
reached 18–22 mm, followed by intrauterine insemination 
(IUI) 36–38 h later. Endometrial thickness was measured 
along the sagittal axis of the uterus between echogenic 
surfaces. We used a low-dose FSH regimen to minimize the 
risk of multiple pregnancies and ovarian hyperstimulation 
syndrome (OHSS. The initial daily dose of rFSH was set to 
75 international units (IU) for 7 days from the third day of 
menstruation. If the follicular diameter did not exceed 9 mm, 
the daily dose was increased to 37.5 IU in the second week.
The primary outcomes were 1) ovulation, defined as 
a progesterone level of > 3 ng/mL between D 21 and 23 and 
2) clinical pregnancy was defined when an intrauterine ges-
tational sac(s) was visible by ultrasonography. Secondary 
outcomes included a multiple pregnancy  and miscarriage.
The study protocol was approved by the regional ethics 
committee of GaziYaşargil Training and Research Hospital 
(approval no: 254).
Statistical analysis
The mean ± standard deviation (SD) were calculated for 
quantitative variables. Qualitative variables are presented as 
frequencies. The normality of the data was checked using 
the Kolmogorov-Smirnow test. Using an alpha value of 0.05, 
the power of our study calculated at 99%. The Student’s 
t-test and Mann–Whitney U test were performed to compare 
continuous variables with and without a normal distribu-
tion in the two groups. The Student’s t-test were performed 
variables with a normal distribution (Age, BMI and EMT in 
Tab. 1). Mann–Whitney U test were performed variables 
without a normal distribution (Other variables in Tab. 1). 
The proportional data were compared using a chi-squared 
test and Fisher’s exact test (in Tab. 2, Ovulation, Pregnancy 
and Follicles, n > 5 using a chi-squared test; Miscarriage and 
Twin foetuses; n < 5 using a Fisher’s exact test).
A p value of < 0.05 was considered significant. All sta-
tistical analyses were performed using R-software v.3.5.1 
(R Statistics Software; Institute for Statistics and Mathematics, 
Vienna, Austria).
RESULTS
One hundred sixteen patients had CC resistant PCOS. 
Seventy (96%) patients in Group 1 and 42 patients in Group 2 
(98%) developed one or more mature follicles on the day 
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of application of the HCG trigger. The mature follicular ratio 
in Group 2 [42/43 (98%)], was higher than that in Group 1 
[70/73 (96%)], but there was no statistically significant dif-
ference between the two groups (p = 0.96). The ovulation 
rate in Group 1 was 65/73 (89%), the pregnancy rate was 
13/73 (18%), the twin foetus rate was 1/73 (1.3%) and the 
miscarriage rate was 2/73 (2.7%). In Group 2, the ovulation 
rate was 41/43 (95%), and the pregnancy rate was 8/43 (19%) 
the twin foetus rate was 1/43(2.3%) and the miscarriage 
rate was 1/43 (2.3%). There was no statistically significant 
difference in the ovulation (p = 0.25), pregnancy (p = 0.91), 
twin foetuses (p = 0.89) and miscarriage p = 0.89) rates 
between two groups.
DISCUSSION
Letrozole and CC have different mechanisms of action; 
These different mechanisms of action of the two drugs 
may complement each other to increase ovulation rates as 
compared to those achieved with gonadotropin use alone 
[3, 8]. In this study, letrozole plus CC was compared with 
gonadotropins in CC-resistant infertile PCOS patients retro-
spectively. There was no statistically significant difference 
in the ovulation and pregnancy rates between two groups.
Previous research found no significant difference in 
pregnancy rates between women with CC-resistant PCOS 
who underwent IUI and were subsequently treated with 
letrozole versus those who were treated with rFSH [13]. Simi-
larly, there was no significant difference in the pregnancy 
rates of women undergoing IUI who were treated with letro-
zole versus those treated with CC plus human menopausal 
gonadotropin [14]. In a retrospective study on 132 women 
with failed CC treatment and various causes of infertility, the 
cumulative pregnancy rate after three cycles of treatment 
with gonadotropins was higher than that after treatment 
with letrozole treatment [15].
There are a few published studies on the use of CC plus 
letrozole. In a study on 100 patients resistant to letrozole 
(four cycles) and CC (six cycles), Hajishafiha et al. [16] reported 
a follicular development rate of 82.9% (213 of 257 cycles) in 
patients treated with 5 mg of letrozole plus 100 mg of CC 
daily for 5 D. In the same study, patients received an FSH in-
jection on d 11 if a dominant follicle was present and received 
HCG trigger when the follicle was > 18 mm in size, followed 
by intrauterine insemination 36–38 h later. In another com-
bination study, the patients were classified according to age 
and BMI and randomized to 2.5 mg of letrozole (n = 35) or 
combination treatment with 2.5 mg of letrozole and 50 mg 
of CC (n = 35) daily for 3–7 [17]. The ovulation rate in the 
CC + letrozole group (27/35, 77%) was significantly higher 
than that in the letrozole only group (15/35, 43%). 
In the studies by Hajishafiha et al. [16] and Mejia et al. [17], 
100 mg of CC plus 5 mg of letrozole and 50 mg of CC plus 
2.5 mg of letrozole were administered for 5 days, respective-
ly. In the present study, the patients received a combination 
of 2.5 mg of letrozole for 3 days (days of menstruation 5–7) 
and 100 mg of CC for 5 days (days of menstruation 3–7 mg) 
for one treatment cycle. The aim of this treatment protocol 
was to determine the effect of short-term low dose letrozole 
use. The ovulation rate in Group 1 was 65/73 (89%), the preg-
nancy rate was 13/73 (18%), In Group 2, the ovulation rate 
was 41/43 (95%), and the pregnancy rate was 8/43 (19%). 
There was no statistically significant difference in the ovula-
tion (p = 0.25), pregnancy (p = 0.91).
Table 1. Demographic and laboratory results of the patients
Group 1
CC + letrozole
(n = 73)
Group 2
Gonadotropins
(n = 43)
p value
Age [years] 
(mean ± SD) 29.54 ± 6.68 30.06 ± 5.17 0.50
BMI [kg/m2] 
(mean ± SD) 21.09 ± 1.48 21.46 ± 1.61 0.28
E2 at HCG 
(mean ± SD) 288.1 ± 121.6. 285.4 ± 127.04 0.71
Progesterone 
[ng/mL] (mean ± SD) 12.64 ± 7.5 13.43 ± 5.7 0.62 
Basal E2 [pg/mL]
(mean ± SD) 46.41 ± 12.01 50.3 ± 11.70 0.81
LH [IU/mL] 
(mean ± SD) 5.08 ± 1.72 4.98 ± 1.68 0.85
FSH [IU/mL] 
(mean ± SD) 5.25 ± 1.40 5.92 ± 1.94 0.86
EMT at HCG [mm] 
(mean ± SD) 9.04 ± 1.25 9.24 ± 1.13 0.77
Duration of infertility 
[years] (mean ± SD) 3.49 ± 0.85 4.14 ± 0.76 0.05
Data are mean ± standard deviation; BMI — body mass index; CC 
— clomiphene citrate; FSH — follicle-stimulating hormone; E2 — oestrodiol; 
HCG — human chorionic gonadotropin; IU — international unit; LH 
— luteinizing hormone; Age, BMI and EMT at HCG (The Student’s t-test were 
performed variables with  a normal distribution) 
Other variables (Mann–Whitney U test were performed variables without 
a normal distribution)
Table 2. Comparison of outcomes according to treatment groups
Group 1
CC + letrozole
(n = 73)
Group 2
Gonadotropins
(n = 43)
P value
Ovulation, n (%) 65 (89) 41 (95) 0.25
Pregnancy, n (%) 13 (18) 8 (19) 0.91
Miscarraige, n (%) 2 (2.7) 1 (2.3) 0.89
Twin foetuses, n (%) 1 (1.3) 1 (2.3) 0.89
Mature Follicles  
≥ 18 mm at HCG, n (%) 70 (96) 42 (98) 0.96
Data are mean n (percentage) 
Ovulation, pregnancy, mature follicle ( n > 5 using a chi-squared test) 
Miscarriage and twin foetuses (n < 5 using a Fisher’s exact test)
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In patients treated with gonadotropins, the multiple 
pregnancy rate was reported to vary between 5 and 20% 
[18]. In other studies, a combination of letrozole and go-
nadotropin in OI cycles resulted in more mono-ovulation 
and a shorter ovulation induction duration [19], in addition 
to a reduced incidence of multiple gestations [6]. Hajishafiha 
et al. [16] reported five cases of twin foetuses (12%) among 
patients treated with gonadotropins, whereas others re-
ported no multiple pregnancy cases following this type of 
treatment [17]. Multiple gestations resulted in higher risk 
of preterm birth and associated neonatal morbidity and 
expens [20]. In our study, one patient in the gonadotro-
pin-treatment group had a twin gestation, but this was not 
statistically significant.
For patients with CC resistance, gonadotropin prepara-
tions have become the first choice. Unfortunately, the use of 
gonadotropins is frequently complicated by the OHSS [20]. 
We had no case of OHSS in our study.
The present study has several limitations. First, since this 
study is retropective, larger prospective studies are needed, 
thus selection bias cannot be excluded. Second, although 
we increased the dose of gonadotropins, we kept the dose 
and duration of CC plus letrozole constant. Third, we did not 
study neonatal outcomes because pregnancies were not fol-
lowed up to delivery. Finally, only one cycle per participant 
was performed (after CC resistance cycles).
CONCLUSIONS
Gonadotropins are the recommended treatment for 
patients with CC-resistant PCOS. However, their use neces-
sitates serial evaluations of hormones and sonographic 
monitoring. This new drug combination suggests that it 
may be a lower cost, lower risk alternative treatment that 
increases the rate of ovulation. Larger randomized clinical 
trials are needed to provide information on live birth rates 
of this combination.
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